首页> 外文会议>Joint Conference on Chemisty >In silico modification of Zn~(2+) binding group of suberoylanilide hydroxamic acid (SAHA) by organoselenium compounds as Homo sapiens class II HDAC inhibitor of cervical cancer
【24h】

In silico modification of Zn~(2+) binding group of suberoylanilide hydroxamic acid (SAHA) by organoselenium compounds as Homo sapiens class II HDAC inhibitor of cervical cancer

机译:通过有机烯化合物作为Zn〜(2+)结合基团的Zn〜(2+)结合基团的Zn〜(2+)结合基团的组织化合物作为宫颈癌的HOMO SAPIENS II HDAC抑制剂

获取原文

摘要

Cervical cancer is the most common cancer in women, and ranks seventh of all cancers worldwide, with 529000 cases in 2008 and more than 85% cases occur in developing countries. One way to treat this cancer is through the inhibition of HDAC enzymes which play a strategic role in the regulation of gene expression. Suberoyl Anilide Hydroxamic Acid (SAHA) or Vorinostat is a drug which commercially available to treat the cancer, but still has some side effects. This research present in silico SAHA modification in Zinc Binding Group (ZBG) by organoselenium compound to get ligands which less side effect. From molecular docking simulation, and interaction analysis, there are five best ligands, namely CC27, HA27, HB28, IB25, and KA7. These five ligands have better binding affinity than the standards, and also have interaction with Zn~(2+) cofactor of inhibited HDAC enzymes. This research is expected to produce more potent HDAC inhibitor as novel drug for cervical cancer treatment.
机译:宫颈癌是女性中最常见的癌症,并在全球所有癌症中排名第七,2008年的529000例,发展中国家出现了超过85%的案件。一种治疗这种癌症的一种方法是通过抑制HDAC酶,这在基因表达的调节中起着战略作用。 Suberoyl苯硅酸羟肟酸(Saha)或vorinostat是一种商业上可用于治疗癌症的药物,但仍有一些副作用。该研究存在于有机烯化合物中锌结合基团(ZBG)的硅酱修饰中,得到副作用较小的配体。从分子对接模拟和相互作用分析中,有五种最佳配体,即CC27,HA27,HB28,IB25和KA7。这五种配体具有比标准的更好的结合亲和力,并且还具有与抑制HDAC酶的Zn〜(2+)辅因子的相互作用。该研究预计将产生更多有效的HDAC抑制剂作为宫颈癌治疗的新药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号